Is enzymatic oligonucleotide production ready for commercial manufacturing?
- 16 hours ago
- 1 min read
As interest in oligonucleotide therapies continues to grow, the industry is exploring new ways to manufacture these complex molecules at scale.
A new article from Centre for Process Innovation (CPI) examines whether enzymatic synthesis could offer a more sustainable alternative to the traditional phosphoramidite chemistry used today.
Enzymatic approaches use biocatalysts to assemble oligonucleotides in water-based systems, with the potential to reduce solvent use, hazardous reagents and purification steps.
